An observational study in Anovulation, sponsored by UMC Utrecht. Status unknown at 1 site in Netherlands. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2021-10-20.
Sponsored by UMC Utrecht · Observational
Through the COLA Study and Biobank the investigators hope to enable further identification of phenotype, endocrine, ethnic, and metabolic characteristics associated with menstrual cycle disturbances; and: the identification of genetic or other etiologic factors associated with cycle disturbances.
Population Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.
Inclusion criteria WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
WHO II
Within women with WHO II status, polycystic ovary syndrome (PCOS) is diagnosed when at least 2 of the following criteria are met:
WHO III
Exclusion criteria
Study parameters In order to determine the phenotype characteristics of women with cycle disturbances, and to allow for the identification of genetic factors associated with cycle disturbances, the following parameters will be obtained.
Participation in the COLA Biobank will consist of the additional withdrawal of two blood vials (one for DNA and one for serum sampling) obtained during the routine diagnostic procedure.
Relatives of the index patient:
When a familial tendency of the WHO status is suspected on the basis of family history of 1st and 2nd degree relatives, these relatives will be invited for participation of the study.
75 studies on the registry are indexed under Anovulation; 7 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 300 across 17 observational studies indexed under Anovulation.
Browse Anovulation studies →UMC Utrecht is the lead sponsor of 364 studies on the registry; 82 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.
Inclusion Criteria:
WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
WHO II
Within women with WHO II status, PCOS is diagnosed when at least 2 of the following criteria are met:
WHO III
Exclusion criteria: Exclusion criteria
WHO I, II. III anovulation. See inclusion criteria
hormonal classification
FSH, LH, Estradiol, Progesterone,Testosterone, Androstenedione, Sex hormone binding globulin (SHBG), Cortisol, TSH
Time frame: within 6 weeks
metabolic profile
total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, insulin, glucose
Time frame: within 6 weeks
ovarian reserve
anti mullerian hormone, FSH and antral follicle count.
Time frame: within 6 weeks
autoimmunity in WHO 3- POI patients
antithyroid peroxidase, antiadrenal, antiparietal and antiovarian antibodies
Time frame: within 3 months
bone density in WHO 3- POI patients
a dual-energy x-ray absorptiometry (DEXA) scan
Time frame: within 3 months
genotype in WHO 3 POI patients
karotype, fragile X mental retardation 1 gene premutation carriership
Time frame: within 3 months
This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.